Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to dep… Read more
Kairos Pharma, Ltd. (KAPA) - Total Liabilities
Latest total liabilities as of September 2025: $402.00K USD
Based on the latest financial reports, Kairos Pharma, Ltd. (KAPA) has total liabilities worth $402.00K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kairos Pharma, Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how Kairos Pharma, Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kairos Pharma, Ltd. Competitors by Total Liabilities
The table below lists competitors of Kairos Pharma, Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turbo Energy, S.A. American Depositary Shares
NASDAQ:TURB
|
USA | $12.08 Million |
|
M2A0
F:M2A0
|
Germany | €1.61 Billion |
|
Corus Entertainment Inc
PINK:CJREF
|
USA | $2.04 Billion |
|
Y/KNOT S.A.
AT:YKNOT
|
Greece | €29.83 Million |
|
T T Limited
NSE:TTL
|
India | ₹936.11 Million |
|
Nuvotec
KQ:060260
|
Korea | ₩32.17 Billion |
|
Induct AS
OL:INDCT
|
Norway | Nkr12.41 Million |
|
Macromill Embrain Co. Ltd
KQ:169330
|
Korea | ₩20.18 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Kairos Pharma, Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kairos Pharma, Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kairos Pharma, Ltd. (2020–2024)
The table below shows the annual total liabilities of Kairos Pharma, Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.44 Million | -52.68% |
| 2023-12-31 | $3.04 Million | +37.38% |
| 2022-12-31 | $2.21 Million | +14.06% |
| 2021-12-31 | $1.94 Million | +443.76% |
| 2020-12-31 | $357.15K | -- |